Run Sheng Jiang
President chez WALVAX BIOTECHNOLOGY CO., LTD.
Fortune : 4 M $ au 31/03/2024
Profil
Run Sheng Jiang is currently the Chairman of Shanghai Zerun Biotechnology Co., Ltd.
and the President & Director of Walvax Biotechnology Co., Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 930 000 ( 0,06% ) | 2 M $ | 31/03/2024 | |
| 30/09/2023 | 773 437 ( 1,64% ) | 2 M $ | 31/03/2024 |
Postes actifs de Run Sheng Jiang
| Sociétés | Poste | Début |
|---|---|---|
| WALVAX BIOTECHNOLOGY CO., LTD. | President | 22/06/2016 |
Shanghai Zerun Biotechnology Co., Ltd.
 Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China. | Chairman | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| WALVAX BIOTECHNOLOGY CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Shanghai Zerun Biotechnology Co., Ltd.
Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China. | Health Technology |
